Probiodrug AG | Mutual Funds
Mutual Funds that own Probiodrug AG
BB Biotech AG
1,050,784
12.84%
0
0.09%
03/31/2018
AXA Framlington Biotech Fund
146,773
1.79%
0
0.07%
02/28/2018
Stichting Pensioenfonds ABP (Global Equity Portfolio)
47,393
0.57%
-24,523
0%
03/31/2018
35,000
0.43%
0
0.03%
06/30/2017
Lupus alpha Fonds - Micro Champions
30,000
0.37%
30,000
0.2%
12/31/2017
Schroder UTL - Global Healthcare
27,750
0.34%
0
0.03%
05/31/2018
Aviva Investors Investment Funds ICVC - European Equity Fund
21,784
0.27%
0
0.03%
10/15/2017
Aviva Investors - European Equity Fund
20,622
0.25%
0
0.04%
06/30/2018
Adamant Global Biotech
15,851
0.19%
-700
0.05%
12/29/2017
12,600
0.15%
0
0.13%
07/26/2018
| Address |
Weinbergweg 22
Halle Sachsen-Anhalt 06120
Germany
|
|
Employees
|
- |
| Website |
http://www.probiodrug.de |
| Updated |
07/08/2019 |
| Probiodrug AG is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its product pipeline includes PQ912, PBD-C06, and PQ1565. The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and is headquartered in Halle, Germany. |
